Antifungal stewardship in daily practice and health economic implications

Mycoses

Volumn 58, Issue S2, 2015, Pages 14-25

  Muñoz, Patricia ^a,b,c   Valerio, Maricela ^a,c   Vena, Antonio ^a,b,c   Bouza, Emilio ^a,b,c  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Antifungal stewardship; Antifungal therapy; Candins; Empiric antifungals; Fluconazole; Invasive candidiasis

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; VORICONAZOLE; ECHINOCANDIN; PYRROLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL STEWARDSHIP PROGRAM; ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG USE; FEBRILE NEUTROPENIA; HEALTH CARE QUALITY; HEALTH ECONOMICS; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE UNIT; PHARMACIST; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; SYSTEMIC MYCOSIS; DRUG UTILIZATION; FUNGEMIA; HEALTH CARE COST; LENGTH OF STAY; STANDARDS; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; AZOLES; DRUG UTILIZATION; ECHINOCANDINS; FUNGEMIA; HEALTH CARE COSTS; HUMANS; LENGTH OF STAY; TREATMENT OUTCOME;

EID: 84929859139     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12329     Document Type: Article

References (40)

1. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-77.
2. Boucher HW. Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication. Clin Infect Dis 2010; 50(Suppl. 1): S4-9.
3. Mondain V, Lieutier F, Hasseine L et al. A 6-year antifungal stewardship programme in a teaching hospital. Infection 2013; 41: 621-8.
4. Cook PP, Catrou PG, Christie JD, Young PD, Polk RE. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother 2004; 53: 853-9.
5. Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol 2012; 33: 338-45.
6. Apisarnthanarak A, Yatrasert A, Mundy LM. Impact of education and an antifungal stewardship program for candidiasis at a Thai tertiary care center. Infect Control Hosp Epidemiol 2010; 31: 722-7.
7. Lopez-Medrano F, San Juan R, Lizasoain M et al. A non-compulsory stewardship programme for the management of antifungals in a university-affiliated hospital. Clin Microbiol Infect 2013; 19: 56-61.
8. Valerio M, Rodriguez-Gonzalez CG, Munoz P, Caliz B, Sanjurjo M, Bouza E. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob Chemother 2014; 69: 1993-9.
9. des Champs-Bro B, Leroy-Cotteau A, Mazingue F et al. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology. J Clin Pharm Ther 2011; 36: 152-60.
10. Aitken SL, Beyda ND, Shah DN et al. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother 2014; 48: 683-90.
11. Valerio M, Vena A, Bouza E et al. How much European prescribing physicians know about invasive fungal infections management? BMC Infect Dis 2015; 15: 80-88.
12. Munoz P, Rojas L, Cervera C et al. Poor compliance with antifungal drug use guidelines by transplant physicians: a framework for educational guidelines and an international consensus on patient safety. Clin Transplant 2012; 26: 87-96.
13. Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant 2008; 8: 426-31.
14. Nivoix Y, Launoy A, Lutun P et al. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. J Antimicrob Chemother 2012; 67: 2506-13.
15. Sutepvarnon A, Apisarnthanarak A, Camins B, Mondy K, Fraser VJ. Inappropriate use of antifungal medications in a tertiary care center in Thailand: a prospective study. Infect Control Hosp Epidemiol 2008; 29: 370-3.
16. Pavese P, Ouachi Z, Vittoz JP et al. Adequacy of new systemic antifungal agents prescriptions in a teaching hospital. Medecine et Maladies Infectieuses 2007; 37(Suppl. 3): S223-8.
17. Bassetti M, Molinari MP, Mussap M, Viscoli C, Righi E. Candidaemia in internal medicine departments: the burden of a rising problem. Clin Microbiol Infect 2013; 19: E281-4.
18. Gonzalez de Molina FJ, Leon C, Ruiz-Santana S, Saavedra P. Assessment of candidemia-attributable mortality in critically ill patients using propensity score matching analysis. Crit Care 2012; 16: R105.
19. Shah DN, Yau R, Weston J et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother 2011; 66: 2146-51.
20. Baddley JW, Patel M, Jones M, Cloud G, Smith AC, Moser SA. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia. Diagn Microbiol Infect Dis 2004; 50: 119-24.
21. Vazquez J, Reboli AC, Pappas PG et al. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC Infect Dis 2014; 14: 97.
22. Charani E, Castro-Sanchez E, Sevdalis N et al. Understanding the determinants of antimicrobial prescribing within hospitals: the role of "prescribing etiquette." Clin Infect Dis 2013; 57: 188-96.
23. Dodds Ashley E, Drew R, Johnson M et al. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. Pharmacother 2012; 32: 890-901.
24. Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis 2012; 25: 107-15.
25. Cappelletty D, Jacobs D. Evaluating the impact of a pharmacist's absence from an antimicrobial stewardship team. Am J Health Syst Pharm 2013; 70: 1065-9.
26. Antworth A, Collins CD, Kunapuli A et al. Impact of an antimicrobial stewardship program comprehensive care bundle on management of candidemia. Pharmacother 2013; 33: 137-43.
27. Swoboda S, Lichtenstern C, Ober MC et al. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemother 2009; 55: 418-24.
28. Guarascio AJ, Slain D, McKnight R et al. A matched-control evaluation of an antifungal bundle in the intensive care unit at a university teaching hospital. Int J Clin Pharm 2013; 35: 145-8.
29. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-93.
30. Aguilar-Guisado M, Martin-Pena A, Espigado I et al. Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach. Haematologica 2012; 97: 464-71.
31. Martin-Pena A, Gil-Navarro MV, Aguilar-Guisado M et al. Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia. Antimicrob Agents Chemother 2013; 57: 4664-72.
32. Barnes RA, Stocking K, Bowden S, Poynton MH, White PL. Prevention and diagnosis of invasive fungal disease in high-risk patients within an integrative care pathway. J Infect 2013; 67: 206-14.
33. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 2015; 60: 892-9.
34. Valerio M, Muñoz P, Rodriguez CG et al. Two years of an antifungal stewardship program. Clin Microbiol Infect 2015. In press.
35. Valerio M, Munoz P, Rodriguez-Gonzalez C, Sanjurjo M, Guinea J, Bouza E. Training should be the first step toward an antifungal stewardship program. Enferm Infecc Microbiol Clin 2014; 33: 221-7.
36. Guinea J, Zaragoza O, Escribano P et al. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother 2014; 58: 1529-37.
37. Escribano P, Rodriguez-Creixems M, Sanchez-Carrillo C, Munoz P, Bouza E, Guinea J. Endemic genotypes of Candida albicans causing fungemia are frequent in the hospital. J Clin Microbiol 2013; 51: 2118-23.
38. Marcos-Zambrano LJ, Escribano P, Sanchez C, Munoz P, Bouza E, Guinea J. Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. Antimicrob Agents Chemother 2014; 58: 4565-72.
39. Escribano P, Pelaez T, Munoz P, Bouza E, Guinea J. Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob Agents Chemother 2013; 57: 2815-20.
40. Martinez-Jimenez MC, Munoz P, Guinea J et al. Potential role of Candida albicans germ tube antibody in the diagnosis of deep-seated candidemia. Med Mycol 2014; 52: 270-5.